Welcome to our dedicated page for Azitra news (Ticker: AZTR), a resource for investors and traders seeking the latest updates and insights on Azitra stock.
Azitra Inc. develops clinical-stage precision dermatology therapies built around engineered proteins and topical live biotherapeutic products. Its pipeline includes ATR-12, an engineered S. epidermidis program for Netherton syndrome; ATR-04, an engineered S. epidermidis candidate for EGFR inhibitor-associated rash; and ATR-01, a program targeting ichthyosis vulgaris through delivery of recombinant human filaggrin.
Azitra news commonly covers patent protection, preclinical and clinical program updates, scientific presentations, business results, financing activity, shareholder meeting matters, and NYSE American listing-compliance notices. Company updates also reference its microbial discovery platform, artificial intelligence and machine-learning screening tools, and the use of genetically engineered bacteria and proteins for dermatology applications.
Azitra (NYSE American: AZTR) plans to open its 2026 annual stockholder meeting on June 4, 2026, then immediately adjourn and reconvene it on June 15, 2026 at 11:00 a.m. Eastern Time in virtual format.
The adjournment allows extra time for stockholders of record on April 24, 2026 to receive and submit proxies via mail, internet, telephone, or during the reconvened webcast at www.proxydocs.com/AZTR. Previously submitted proxies remain valid unless changed.
Azitra (NYSE American: AZTR) reported Q1 2026 results and outlined clinical and strategic progress in precision dermatology.
Key updates include adding MD Anderson as an ATR-04 trial site, advancing ATR-12 Phase 1b in Netherton syndrome, launching a filaggrin-based cosmeceutical initiative, new U.S. patent coverage for ATR-12, and pricing up to $10.5 million in private placement financing.
Q1 2026 R&D expenses were $1.6 million, G&A $2.4 million, net loss $3.9 million, and cash $10.1 million.
Azitra (NYSE American: AZTR) announced issuance of U.S. Patent No. 12,606,610 B2 on April 21, 2026, titled "Compositions and Methods for Treatment of Netherton Syndrome with LEKTI Expressing Recombinant Microbes."
The patent covers microbes that secrete LEKTI domains and methods to treat skin diseases and provides broad protection for ATR-12, which is in a Phase 1b trial for Netherton syndrome (≈20,000 patients globally).
Azitra (NYSE American: AZTR) will present preclinical data for ATR-01 at ASGCT 2026 showing ATR01-616 delivers recombinant human filaggrin to skin, reduces transepidermal water loss (TEWL) in ex vivo pig skin (p < 0.001), and restores filaggrin and keratin co-localization in reconstructed human epidermis.
The poster supports advancement toward IND-enabling studies and a planned first-in-human trial in ichthyosis vulgaris.
Azitra (NYSE: AZTR) priced a private placement providing gross proceeds of up to $31.4 million, including initial gross proceeds of $10.5 million and up to an additional $20.9 million upon potential cash exercise of warrants.
The financing issues 10,470 Series A preferred shares, Series B and C warrants exercisable at $0.123 per share, and supports new protein and peptide R&D for cosmetic and cosmeceutical commercialization.
Azitra (NYSE: AZTR) received a NYSE American notice of non-compliance under Sections 1003(a)(ii) and 1003(a)(iii) for minimum stockholders' equity requirements and has until April 1, 2027 to regain compliance. The Exchange accepted Azitra's previously submitted Plan on December 16, 2025.
The company noted an audit opinion including a going concern paragraph in its Form 10-K for the year ended December 31, 2025. Azitra will remain listed during the plan period while exploring multiple funding avenues.
Azitra (NYSE: AZTR) announced cancellation of its special meeting of stockholders that had been originally scheduled for February 6, 2026 and adjourned to March 6, 2026 due to a lack of quorum.
The company is a clinical‑stage biopharmaceutical developer of engineered S. epidermidis programs, including ATR-12 (Phase 1b for Netherton syndrome) and ATR-04 (FDA Fast Track for EGFRi associated rash; open IND). Azitra’s platform includes ~1,500 bacterial strains and AI/ML screening tools.
Azitra (NYSE American: AZTR) reported full-year 2025 results and clinical progress. Key clinical advances include dosing the first patient in the Phase 1/2 ATR-04 trial (EGFRi-associated rash), Fast Track designation for ATR-04, promising Phase 1b safety data for ATR-12 in Netherton syndrome, and positive preclinical ATR-01 data.
Financials: R&D $4.8M, G&A $6.2M, net loss $11.0M, and cash & equivalents $2.1M; completed $8.5M financing activity in 2025.
Azitra (NYSE:AZTR) added The University of Texas MD Anderson Cancer Center as a clinical site for its Phase 1/2 study of topical ATR-04 (ATR04-484) for EGFR inhibitor-associated skin rash.
The multicenter, randomized, double-blind study (NCT06830863) is enrolling Cohort 1 (anticipated eight patients). ATR-04 has FDA Fast Track designation and an open IND.
Azitra (NYSE American: AZTR) will present at the BIO Investment & Growth Summit in Miami Beach on March 2-3, 2026, with a formal presentation on March 2 at 2:15 PM ET.
Management will highlight pipeline updates for ATR-12 (Phase 1b), ATR-04 (Phase 1/2) and ATR-01 (IND-enabling), and hold one-on-one investor meetings.